The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
A longitudinal All of Us analysis found that 34.3% of adults classified with preclinical obesity developed obesity-related functional impairment or illness within five years. The result supports closer study of a new diagnostic framework but does not establish how individual patients should be treated.
FDA’s written pre-IND feedback did not identify issues that the company says would prevent an application for a U.S. trial of PT00114 in generalized anxiety disorder. The exchange is an early regulatory milestone—not authorization to begin the trial or evidence that the peptide treats anxiety.
A harmonized analysis of 51 longitudinal intervention studies found that newer DNA-methylation clocks were more responsive than clocks trained mainly to estimate chronological age. Responsiveness, however, does not establish that a clock change predicts longer life or better health.
BMAL1 and YAP normally help maintain epidermal identity, but experiments suggest their genomic activity shifts toward inflammatory programs in aged mouse skin. The work identifies a mechanism for further study, not a validated treatment for skin aging or systemic inflammation.
A revised FDA import alert adds orforglipron products and spells out the evidence manufacturers may need to avoid detention. The action targets supply-chain quality, not the clinical effectiveness of GLP-1 medicines.
A randomized, sham-controlled trial found no overall reduction in postoperative delirium after a single session of transcranial electrical stimulation. A favorable subgroup signal after longer operations is exploratory, not evidence of benefit.
Blood profiling of 28 older Japanese adults found progressively larger populations of cytotoxic CD4 T cells among centenarians and supercentenarians. The finding suggests continued immune adaptation in extreme old age, but it does not show that these cells prevent cancer or extend life.
Merck and Moderna say individualized mRNA therapy intismeran plus Keytruda delayed melanoma recurrence and distant spread compared with Keytruda alone. The topline announcement did not disclose effect sizes, detailed safety findings, or overall-survival results.
Modeled global rates of blindness and vision loss attributed to type 2 diabetes increased among adults aged 20–39 between 1990 and 2021. The study identifies a growing prevention concern but cannot establish why rates changed or substitute for country-level surveillance.
A large observational study linked higher scores on a newly developed dietary pattern to lower aging-related mortality and more favorable biomarker profiles. The result is a hypothesis-generating nutrition model, not evidence that following the score will extend life.
The FcRn-blocking biologic improved a composite disease-activity score in adults with immune-mediated necrotizing myopathy or dermatomyositis. The company has released topline findings, but detailed efficacy and safety data remain unavailable.
A new FDA discussion paper considers evaluating generative-AI medical devices through clinical benchmarks, real-world confirmation, and continuing surveillance. The proposal is an early request for feedback—not guidance or a change in regulatory requirements.